NEWBIE
2021-11-17
Will they?
Will Investors Win With Johnson & Johnson's Planned Spinoff? Here's What History Shows
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
6
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":878383903,"tweetId":"878383903","gmtCreate":1637149336364,"gmtModify":1637149336563,"author":{"id":3573124416025977,"idStr":"3573124416025977","authorId":3573124416025977,"authorIdStr":"3573124416025977","name":"NEWBIE","avatar":"https://static.tigerbbs.com/3efe20248e6d34805e6c7befc3ae66a0","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":51,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Will they?</p></body></html>","htmlText":"<html><head></head><body><p>Will they?</p></body></html>","text":"Will they?","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/878383903","repostId":2184832463,"repostType":4,"repost":{"id":"2184832463","kind":"highlight","pubTimestamp":1637148762,"share":"https://www.laohu8.com/m/news/2184832463?lang=&edition=full","pubTime":"2021-11-17 19:32","market":"us","language":"en","title":"Will Investors Win With Johnson & Johnson's Planned Spinoff? Here's What History Shows","url":"https://stock-news.laohu8.com/highlight/detail?id=2184832463","media":"Motley Fool","summary":"Past spinoffs by other companies could bode well overall for J&J shareholders.","content":"<p>The biggest healthcare company in the world is preparing to shrink. <b>Johnson & Johnson</b> (NYSE:JNJ) announced last week that it plans to spin off its consumer healthcare business into a separate publicly traded entity.</p>\n<p>J&J said that this move will unlock shareholder value and accelerate growth. But will investors really win with the planned spinoff? Here's what history shows.</p>\n<h2>Three other spinoffs</h2>\n<p><b>Pfizer</b> (NYSE:PFE) and <b>GlaxoSmithKline</b> established a joint venture for their consumer health units. However, the business won't spin off until next year so we don't know how the move will impact the companies. We can look at how a couple of Pfizer's other spinoffs have fared, though.</p>\n<p>In February 2013, Pfizer spun off its animal health business, creating <b>Zoetis</b> (NYSE:ZTS). That transaction turned out to be tremendously successful for Pfizer shareholders who held onto their Zoetis stock. The animal health company went on to trounce the S&P 500. On the other hand, Pfizer lagged well behind the index.</p>\n<p><img src=\"https://static.tigerbbs.com/08f7da003c00bf621b384579149c7268\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>ZTS data by YCharts</p>\n<p>Zoetis was already delivering strong growth, though. J&J's consumer health unit isn't such a great growth driver. Perhaps a better comparison is Pfizer's spinoff and merger in November of last year of its biosimilars and generics business with Mylan to form <b>Viatris</b> (NASDAQ:VTRS). How has that deal rewarded investors? It's a much different story than the Zoetis spinoff.</p>\n<p><img src=\"https://static.tigerbbs.com/edb3cc99431ba26255350506b972a3c4\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>PFE data by YCharts</p>\n<p>In this case, the slower-growth Viatris has languished. Meanwhile, Pfizer has been on a tear thanks to success for its COVID-19 vaccine and tremendous potential for its experimental COVID-19 pill.</p>\n<p>A third recent spinoff could also be instructive. <b>Merck</b> (NYSE:MRK) completed the divestiture of its women's health business in June, creating <b>Organon</b> (NYSE:OGN). Neither of the stocks has kept pace with the S&P 500 since.</p>\n<p><img src=\"https://static.tigerbbs.com/7a9d09c21bdfdbfe899400740f6f5ecc\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>MRK data by YCharts</p>\n<h2>The gold standard</h2>\n<p>We can't leave out what arguably deserves to be called the gold standard of spinoffs. In 2013, <b>Abbott</b> (NYSE:ABT) created <b>AbbVie</b> (NYSE:ABBV). Abbott retained the established pharmaceuticals, diagnostics, medical devices, and nutrition businesses. AbbVie took the innovative pharmaceuticals business, with autoimmune disease drug Humira as its primary star.</p>\n<p>Shareholders were huge winners from this transaction. Both Abbott and AbbVie went on to achieve solid success, performing much better than Abbott had in the previous years.</p>\n<p><img src=\"https://static.tigerbbs.com/4be29c585ed0a203a216d4b4a7d0f3b8\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>ABT data by YCharts</p>\n<p>Going into the spinoff of AbbVie, Abbott was already a member of the Dividend Aristocrats -- an exclusive group of S&P 500 members with consecutive dividend increases for at least 25 years. Importantly, both Abbott and AbbVie have kept their streaks of dividend hikes going. Income investors who held onto their shares of both stocks have done very well.</p>\n<h2>Lessons from the past</h2>\n<p>Can we really learn anything from history about how Johnson & Johnson shareholders might fare with the spinoff of the consumer healthcare business? I think so.</p>\n<p>Perhaps most importantly, a faster-growing business is likely to experience accelerated momentum after the spinoff of a slower-growing business. That's what happened with Zoetis, with Pfizer after the Viatris transaction, and to a lesser extent with Merck after spinning off Organon.</p>\n<p>However, we can also see from the past that things don't always turn out as expected. For example, Some might have predicted that AbbVie would be the stronger performer after the separation. But Abbott's innovation has paid off in a huge way with products including FreeStyle Libre continuous glucose monitoring system and its BinaxNOW COVID-19 tests serving as key growth drivers.</p>\n<p>In addition, companies that prioritized their dividends before a spinoff continued to do so afterward. Abbott and AbbVie are great examples of this. So is Pfizer. The big drugmaker still has an attractive dividend even after spinning off Zoetis and Viatris.</p>\n<p>Of course, there are limits to how much we can extrapolate from past spinoffs and apply to Johnson & Johnson. The healthcare giant's deal won't be exactly like any of the transactions made by other companies in previous years.</p>\n<p>But my prediction is that Johnson & Johnson shareholders will enjoy stronger growth once the consumer unit is a stand-alone entity. I also think that investors who have come to depend on J&J's dividend won't have any worries. This is definitely a surprising move by Johnson & Johnson, but it's <a href=\"https://laohu8.com/S/AONE.U\">one</a> that I expect will pay off over the long term.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Investors Win With Johnson & Johnson's Planned Spinoff? Here's What History Shows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Investors Win With Johnson & Johnson's Planned Spinoff? Here's What History Shows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-17 19:32 GMT+8 <a href=https://www.fool.com/investing/2021/11/17/will-investors-win-with-johnson-johnsons-planned-s/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biggest healthcare company in the world is preparing to shrink. Johnson & Johnson (NYSE:JNJ) announced last week that it plans to spin off its consumer healthcare business into a separate publicly...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/17/will-investors-win-with-johnson-johnsons-planned-s/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4211":"区域性银行","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","JNJ":"强生","BK4504":"桥水持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4007":"制药","ISBC":"投资者银行","BK4532":"文艺复兴科技持仓"},"source_url":"https://www.fool.com/investing/2021/11/17/will-investors-win-with-johnson-johnsons-planned-s/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2184832463","content_text":"The biggest healthcare company in the world is preparing to shrink. Johnson & Johnson (NYSE:JNJ) announced last week that it plans to spin off its consumer healthcare business into a separate publicly traded entity.\nJ&J said that this move will unlock shareholder value and accelerate growth. But will investors really win with the planned spinoff? Here's what history shows.\nThree other spinoffs\nPfizer (NYSE:PFE) and GlaxoSmithKline established a joint venture for their consumer health units. However, the business won't spin off until next year so we don't know how the move will impact the companies. We can look at how a couple of Pfizer's other spinoffs have fared, though.\nIn February 2013, Pfizer spun off its animal health business, creating Zoetis (NYSE:ZTS). That transaction turned out to be tremendously successful for Pfizer shareholders who held onto their Zoetis stock. The animal health company went on to trounce the S&P 500. On the other hand, Pfizer lagged well behind the index.\n\nZTS data by YCharts\nZoetis was already delivering strong growth, though. J&J's consumer health unit isn't such a great growth driver. Perhaps a better comparison is Pfizer's spinoff and merger in November of last year of its biosimilars and generics business with Mylan to form Viatris (NASDAQ:VTRS). How has that deal rewarded investors? It's a much different story than the Zoetis spinoff.\n\nPFE data by YCharts\nIn this case, the slower-growth Viatris has languished. Meanwhile, Pfizer has been on a tear thanks to success for its COVID-19 vaccine and tremendous potential for its experimental COVID-19 pill.\nA third recent spinoff could also be instructive. Merck (NYSE:MRK) completed the divestiture of its women's health business in June, creating Organon (NYSE:OGN). Neither of the stocks has kept pace with the S&P 500 since.\n\nMRK data by YCharts\nThe gold standard\nWe can't leave out what arguably deserves to be called the gold standard of spinoffs. In 2013, Abbott (NYSE:ABT) created AbbVie (NYSE:ABBV). Abbott retained the established pharmaceuticals, diagnostics, medical devices, and nutrition businesses. AbbVie took the innovative pharmaceuticals business, with autoimmune disease drug Humira as its primary star.\nShareholders were huge winners from this transaction. Both Abbott and AbbVie went on to achieve solid success, performing much better than Abbott had in the previous years.\n\nABT data by YCharts\nGoing into the spinoff of AbbVie, Abbott was already a member of the Dividend Aristocrats -- an exclusive group of S&P 500 members with consecutive dividend increases for at least 25 years. Importantly, both Abbott and AbbVie have kept their streaks of dividend hikes going. Income investors who held onto their shares of both stocks have done very well.\nLessons from the past\nCan we really learn anything from history about how Johnson & Johnson shareholders might fare with the spinoff of the consumer healthcare business? I think so.\nPerhaps most importantly, a faster-growing business is likely to experience accelerated momentum after the spinoff of a slower-growing business. That's what happened with Zoetis, with Pfizer after the Viatris transaction, and to a lesser extent with Merck after spinning off Organon.\nHowever, we can also see from the past that things don't always turn out as expected. For example, Some might have predicted that AbbVie would be the stronger performer after the separation. But Abbott's innovation has paid off in a huge way with products including FreeStyle Libre continuous glucose monitoring system and its BinaxNOW COVID-19 tests serving as key growth drivers.\nIn addition, companies that prioritized their dividends before a spinoff continued to do so afterward. Abbott and AbbVie are great examples of this. So is Pfizer. The big drugmaker still has an attractive dividend even after spinning off Zoetis and Viatris.\nOf course, there are limits to how much we can extrapolate from past spinoffs and apply to Johnson & Johnson. The healthcare giant's deal won't be exactly like any of the transactions made by other companies in previous years.\nBut my prediction is that Johnson & Johnson shareholders will enjoy stronger growth once the consumer unit is a stand-alone entity. I also think that investors who have come to depend on J&J's dividend won't have any worries. This is definitely a surprising move by Johnson & Johnson, but it's one that I expect will pay off over the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":221,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":9,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/878383903"}
精彩评论